13
Total deals
$23.1B
Total value
$2.1B
Avg deal
$7.3B
Largest
| # | Acquired | Date | Type | Status | Price | |
|---|---|---|---|---|---|---|
| 1 |
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delive…
|
2026-03-31 | Acquisition | Pending | $5.6B | Deal → |
| 2 |
Alcyone Therapeutics
Alcyone Therapeutics is Pioneering Next-Generation Precision CNS Genetic Therapi…
|
2025-09-18 | Acquisition | Complete | $85.0M | Deal → |
| 3 |
HI-Bio
Human Immunology Biosciences is a biotechnology company that focuses on developi…
|
2024-05-22 | Acquisition | Complete | $1.8B | Deal → |
| 4 |
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for can…
|
2023-07-28 | Acquisition | Complete | $7.3B | Deal → |
| 5 |
Nightstar Therapeutics
Nightstar is biopharmaceutical company, focused on developing gene therapies for…
|
2019-03-04 | Acquisition | Complete | $800.0M | Deal → |
| 6 |
Remedy Pharmaceuticals
Remedy Pharmaceuticals is a clinical stage pharmaceutical company that develops …
|
2017-05-18 | Acquisition | Complete | $120.0M | Deal → |
| 7 |
Convergence Pharmaceuticals
Convergence Pharmaceuticals is a biotechnology company focused on the developmen…
|
2015-01-11 | Acquisition | Complete | $675.0M | Deal → |
| 8 |
Stromedix
Storemedix is a biomedical company focused on drugs for fibrosis, organ failure …
|
2014-02-14 | Acquisition | Complete | $75.0M | Deal → |
| 9 |
Tysabri
Medicine
|
2013-02-01 | — | Complete | — | Deal → |
| 10 |
Syntonix Pharmaceuticals
Syntonix Pharmaceuticals is a biopharmaceutical company that focuses on the rese…
|
2007-01-04 | Acquisition | Complete | $120.0M | Deal → |
| 11 |
F
Fumapharm
Fumapharm is a privately held pharmaceutical company.
|
2006-05-31 | Acquisition | Complete | — | Deal → |
| 12 |
Conforma Therapeutics
Conforma Therapeutics Corporation designs and develops drugs for the treatment o…
|
2006-05-03 | Acquisition | Complete | $150.0M | Deal → |
| 13 |
IDEC Pharmaceuticals
IDEC Pharmaceuticals develop therapies for the treatment of neurodegenerative, h…
|
2003-06-24 | Merge | Complete | $6.4B | Deal → |